AZ weathers another storm as NICE prepares final blow for Faslodex
This article was originally published in Scrip
Executive Summary
More bad news for AstraZeneca. In a week when the company announced that its investigational antidepressant TC-5214, developed in collaboration with Targacept, failed its first Phase III trial (scripintelligence.com, 7 November 2011), NICE, the health technology appraisal institute for England and Wales, today reiterated its concerns that there was little proof that the company's breast cancer drug Faslodex (fulvestrant) was any better than aromatase inhibitors. The institute has published final draft guidance again rejecting the drug for NHS funding.